Big Pharma Has A Rare Week

by MARTHA ROSENBERG

The sound you hear is Pharma swinging from the rafters. Two news stories this week may reinfuse revenue streams in an industry whose blockbuster pill “bubble” has burst.  As Lipitor, Seroquel, Zyprexa, Singulair, Concerta and several other drugs have lost patent protection, Pharma is shedding both employees and ad campaigns. WebMD, the voice of Pharma on the Web, announced it would cut 250 positions in December and medical journals like the Journal of the American Medical Association (JAMA) and New England Journal of Medicine are noticeably thinner without the Pharma ads that have leavened them for years.

Vitamin D and calcium will not protect older women from fractures, a government task force reported this week, in the Annals of Internal Medicine. The U.S. Preventive Services Task Force “recommends against daily supplementation with 400 IU or less of vitamin D3 and 1000 mg or less of calcium for the primary prevention of fractures” and  also recommends that older women, and younger ones with risk factors, be screened for osteoporosis.

While the report does not recommend expensive drugs or seem to be penned by Pharma consultants, its message is still good news for Pharma whose anti-osteoporosis drugs carried it through the 2000s.  “Don’t rely on just Vitamin D and calcium” and “get a bone scan!” were the marketing messages of the bone drugs Boniva, Fosamax and Actonel.

According to published reports, Merck, who launched the bone drug category with its Fosamax, single handedly initiated the “bone scan” craze foisted on middle aged and older women, including setting up a bone “institute” to secure Medicare reimbursement for the scans which were driving Fosamax sales.

Pharma even created the term “osteopenia”–at risk of osteoporosis–to sell the now discredited bone drugs, which are linked to esophageal cancer, osteonecrosis of the jaw, irregular heart beat, pain and actually causing fractures. Subsequent medical reports found the heavily marketed bone scans only benefit 10 percent of women who get them.

In more good news for Pharma this week, Genentech’s drug for allergic asthma, Xolair, co-marketed with Novartis, was trumpeted as having a new possible indication of treating patients with chronic hives or chronic idiopathic urticaria, reported the New York Times. If approved for the new indication, chronic idiopathic urticaria will likely became a major U.S. health problem to be advertised on TV like restless legs syndrome. Ka-ching.

Genetically engineered drugs like Xolair (called monoclonal antibodies) cost as much as $20,000 a year and cause TB, cancers and super infections according to their labels because they suppress the immune system. Xolair was investigated by the FDA for links to heart attack and stroke and 77 people who took Xolair had life-threatening allergic responses in a year and a half, according to FDA reports.

Some of the clinical tests to determine Xolair’s safety were conducted at Vivra which was investigated twice by the FDA for procedural irregularities. Trials of Xolair and at least seven other drugs were corrupted by protocol violations and outright falsifications, according to a former clinical research subinvestigator who worked at the facility. San Mateo, Calif.-based Vivra Asthma & Allergy was the nation’s largest respiratory disease physician practices until a merger with Lakewood, Colo.-based Gambro in 1997 and with El Segundo, Calif.-based DaVita in 2005.

There is even a genetically engineered monoclonal antibody drug called Prolia to treat osteoporosis that costs $1,650 a year now that we know Vitamin D and calcium don’t work.

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

Like What You’ve Read? Support CounterPunch
August 31, 2015
Michael Hudson
Whitewashing the IMF’s Destructive Role in Greece
Conn Hallinan
Europe’s New Barbarians
Lawrence Ware
George Bush (Still) Doesn’t Care About Black People
Joseph Natoli
Plutocracy, Gentrification and Racial Violence
Franklin Spinney
One Presidential Debate You Won’t Hear: Why It is Time to Adopt a Sensible Grand Strategy
Dave Lindorff
What’s Wrong with Police in America
Louis Proyect
Jacobin and “The War on Syria”
Lawrence Wittner
Militarism Run Amok: How Russians and Americans are Preparing Their Children for War
Binoy Kampmark
Tales of Darkness: Europe’s Refugee Woes
Ralph Nader
Lo, the Poor Enlightened Billionaire!
Peter Koenig
Greece: a New Beginning? A New Hope?
Dean Baker
America Needs an “Idiot-Proof” Retirement System
Vijay Prashad
Why the Iran Deal is Essential
Tom Clifford
The Marco Polo Bridge Incident: a History That Continues to Resonate
Peter Belmont
The Salaita Affair: a Scandal That Never Should Have Happened
Weekend Edition
August 28-30, 2015
Randy Blazak
Donald Trump is the New Face of White Supremacy
Jeffrey St. Clair
Long Time Coming, Long Time Gone
Mike Whitney
Looting Made Easy: the $2 Trillion Buyback Binge
Alan Nasser
The Myth of the Middle Class: Have Most Americans Always Been Poor?
Rob Urie
Wall Street and the Cycle of Crises
Andrew Levine
Viva Trump?
Ismael Hossein-Zadeh
Behind the Congressional Disagreements Over the Iran Nuclear Deal
Lawrence Ware – Marcus T. McCullough
I Won’t Say Amen: Three Black Christian Clichés That Must Go
Evan Jones
Zionism in Britain: a Neglected Chronicle
John Wight
Learning About the Migration Crisis From Ancient Rome
Andre Vltchek
Lebanon – What if it Fell?
Charles Pierson
How the US and the WTO Crushed India’s Subsidies for Solar Energy
Robert Fantina
Hillary Clinton, Palestine and the Long View
Ben Burgis
Gore Vidal Was Right: What Best of Enemies Leaves Out
Suzanne Gordon
How Vets May Suffer From McCain’s Latest Captivity
Robert Sandels - Nelson P. Valdés
The Cuban Adjustment Act: the Other Immigration Mess
Uri Avnery
The Molten Three: Israel’s Aborted Strike on Iran
John Stanton
Israel’s JINSA Earns Return on Investment: 190 Americans Admirals and Generals Oppose Iran Deal
Bill Yousman
The Fire This Time: Ta-Nehisi Coates’s “Between the World and Me”
Scott Parkin
Katrina Plus Ten: Climate Justice in Action
Michael Welton
The Conversable World: Finding a Compass in Post-9/11 Times
Brian Cloughley
Don’t be Black in America
Kent Paterson
In Search of the Great New Mexico Chile Pepper in a Post-NAFTA Era
Binoy Kampmark
Live Death on Air: The Killings at WDBJ
Gui Rochat
The Guise of American Democracy
Emma Scully
Vultures Over Puerto Rico: the Financial Implications of Dependency
Chuck Churchill
Is “White Skin Privilege” the Key to Understanding Racism?
Kathleen Wallace
The Id(iots) Emerge
Andrew Stewart
Zionist Hip-Hop: a Critical Look at Matisyahu
Gregg Shotwell
The Fate of the UAW: Study, Aim, Fire